Tactile Systems Technology, Inc. (TCMD) Earnings Call Transcript
February 17, 2026
Earnings Call Speaker Segments
Thanks for joining us this afternoon. With me from Tactile's leadership are CEO Sheri Dodd and CFO Elaine Birkemeyer. Before we begin, please keep in mind that answers we give to your questions during this call might contain forward-looking statements. Such statements reflect what management currently anticipates and come with risks and uncertainties that are inherent; outcomes may end up materially different from what's projected, including the risks described under the Risk Factors portion of the annual report on Form 10-K that we intend to submit to the Securities and Exchange Commission, as well as the 10-K we most recently filed. You can find updates to those factors from time to time in our SEC filings, which are posted on our website. We're not obligated to publicly update or revise any forward-looking statements because of new information, future events, or anything else. On today's call, we'll also mention some financial measures that aren't calculated under generally accepted accounting principles, or GAAP. We usually call these non-GAAP financial measures. If you want to see how those non-GAAP financial measures compare to the most comparable GAAP measures, reconciliations are included in the earnings press release, which is available in the investor relations section of our website. With that, I'll hand the call over to Sheri.
Thanks, Sam. Good afternoon, everyone, and welcome to the call covering our fourth quarter and full year 2025 results. Elaine Birkemeyer, who serves as our Chief Financial Officer, is here with me. For Tactile Medical, 2025 was a pivotal year. We kept advancing our mission of improving life for over 95,000 patients coping with lymphedema and chronic inflammatory lung disease, and we also strengthened the groundwork of our business so it can scale. By executing our commercial and operational strategies with discipline, we delivered strong, profitable revenue growth and simultaneously kept making essential investments in our people and in workflow-related processes. Total revenue for the full year reached $329.5 million, which represents a 12% increase compared with the prior year. Looking past revenue, our gross margin for the full year improved by 190 basis points compared with the previous year, coming in at 75.9%, while Adjusted EBITDA climbed 21% versus a year earlier, hitting $44.8 million. Turning to cash, we repaid the full remaining principal amount of $26.3 million, which retired our term loan, and we repurchased $26.5 million worth of our shares. As 2025 came to a close, we held $83.4 million in cash and cash equivalents, and we generated just under $43 million of operating cash flow over the course of the year. That strong cash generation is sustainable and allows us to continue putting money back into the business and fuel growth throughout 2026 and afterward. Staying focused on strategy, refinement, and execution across 2025 led us to a solid Q4. During the fourth quarter, the commercial momentum we talked about on our previous call continued, and we achieved 21% year-over-year growth in total Q4 revenue, which came to $103.6 million. Looking at our business lines, lymphedema revenue rose 16% compared with a year earlier, reaching $89.5 million, while airway clearance revenue increased 66% year-over-year to $14.1 million. As we look toward 2026, we anticipate total revenue landing somewhere between $357 million and $365 million, which would mean year-over-year growth of 8% to 11%. That forecast takes into account the strength of our expanded sales force, gains in sales rep productivity, and our leading market positions in both lymphedema and airway clearance therapy, and it also factors in a possible near-term market effect from the Medicare prior authorization requirement for pneumatic compression devices that was announced recently. Equally significant, the guidance we're giving accounts for our track record of adjusting smoothly and delivering results even as reimbursement rules keep shifting. Elaine is going to walk through the specifics behind that guidance, along with the newly introduced prior authorization mandates, in a few minutes. Beyond the robust results we posted for Q4 and 2025, we also used this afternoon to reveal that we are buying LymphaTech — a medical technology firm that has stayed privately held and is breaking new ground with an original method for evaluating and tracking fluid buildup in people dealing with chronic swelling conditions like lymphedema. This marks a genuinely thrilling step as Tactile grows beyond being a product-focused business into a full-scale, integrated leader in lymphedema solutions, and my sense is that it carries substantial promise: sharper detection of lymphatic dysfunction, greater uptake of lymphedema therapy, and fresh abilities to shape how we build products down the road. In the rest of today's call, I'll walk through how each business line contributed to our solid fourth-quarter results, and afterward I'll go deeper on the LymphaTech deal. Following that, I'll share where things stand on the strategic priorities we're pursuing, which we expect will keep building momentum as we move through 2026. As a quick reminder, those goals center on three things: making it simpler to access care; widening the range of treatments we offer so that patient outcomes get better and our position as market leader grows even stronger; and increasing the lifetime value of every patient by pairing products with services, given that the conditions we treat are chronic. Elaine will then walk through our complete Q4 results and what we expect for 2026; so with that, let's dive into a closer look at how we performed in the fourth quarter. Within our lymphedema business line, revenue rose 16% compared with the same period a year earlier and 24% over the prior quarter in Q4, which shows lasting momentum and how solid our rebound has been across the last several quarters. What drove these results lines up with what we called out before and shows we keep executing our go-to-market commercial strategy, one that brings together people and technology. On the people side, like we said last quarter, we hit our goal for sales rep hiring by year-end and stay happy with how strong our newly brought-on reps are. This stage of our go-to-market strategy is now complete, and we feel we have the right rep coverage to satisfy and push demand in every geographic location. We restructured the way our sales organization is set up and brought people on board more quickly, which got us to a point where each product specialist is matched by a single account manager. That way of staffing things should keep output strong and sustainable, since folks in the field have to handle both clinical selling and order support. Now that our go-to-market playbook is finished, we'll bring on additional field personnel in a deliberate way whenever the need arises, while continuing to refine how territories are divided and expanding as time goes on. Sales productivity got yet another lift from technology — one example being the CRM launch we did in February of last year. Over the past year, the CRM capabilities we rolled out and enhanced delivered a lot of value when it came to seeing what's happening, staying accountable, and selling more effectively. We'll continue improving that tool by adding more features and upgrading functionality — things like extra data and analytics — so that our field team has the resources and insights it needs to drive referral growth and customer value. Our confidence in the market, and in the way we execute commercially, runs deep. With clear territory design, thoughtful staffing of resources, a robust and well-integrated CRM, and comprehensive strategies and tactics across provider channels, we're positioned well for 2026 and the years ahead. When it comes to our payer mix, our Medicare channel stayed especially robust in Q4, pushed by a couple of factors. Beyond continuing to lap a weaker prior year comparison that came from the documentation challenges starting in Q2 of 2024, we also started seeing patients who satisfied the new NCD unique characteristics requirement go straight to our Flexitouch Advanced pump once they finished conservative therapy, without first going through a basic pump trial. That is a major win for patients, since it speeds up their path to the therapy best suited to their condition, and we are glad to see this momentum building. Now shifting to airway clearance for the patients we support who have chronic inflammatory lung disease. AffloVest revenue rose 66% versus the prior-year period and climbed 6% quarter over quarter during Q4, capping off a remarkable year for that product line; this outcome has us delighted, and it demonstrates how well our targeted commercial approach has been carried out by our talented airway clearance field organization. Demand for AffloVest keeps growing as knowledge of bronchiectasis and the treatment choices available for it becomes more widespread. Although claims information trails behind, we think a market-leading spot in the airway clearance segment has now been attained by us, given that our commercial momentum is building, backed by the robust partnerships and prioritized placement agreements we have locked in with the top ten respiratory DMEs; for 2026, we anticipate airway clearance growth will settle into a more typical pattern relative to the heightened level seen in 2025. When it comes to commercial execution, our ongoing focus will remain on the things that have served us so effectively up to now: making our ties with every one of our top DME partners stronger, going deeper inside those accounts, delivering excellent medical education and training to providers along with DME staff, and bringing to market an improved AffloVest therapy so patients are better served. Having set that context around our Q4 results, I'd like to turn now to examining our purchase of LymphaTech in greater depth.
To build on what we said earlier, this marks a thrilling step forward for Tactile — one that widens what we can currently do while deepening our research and development. More precisely, through LymphaTech, our existing leading portfolio of lymphedema solutions gains digital 3D scanning technology for measuring and monitoring chronic swelling, and at the same time our R&D grows through fresh expertise and initiatives aimed at taking LymphaTech's present abilities toward next-generation methods of assessing and treating disease. Considered as a whole, this deal reinforces our market leadership in conditions tied to lymphatic dysfunction, and we anticipate it will add meaningfully to our strategic priorities of improving access to care, broadening treatment choices, and increasing lifetime patient value. LymphaTech's core technology is a handheld, clinically validated offering that leverages proprietary algorithms and mobile scanning to produce highly accurate fluid volume and precise circumference measurements. Those factors, together with skin changes, matter greatly for spotting lymphedema and guiding the right therapy options. The LymphaTech platform instantly creates a full clinical-grade 3D model of the body and limbs, doing away with conventional manual measurement approaches that take a lot of time, vary widely, and hinge on clinician technique. Paired with a clinician's assessment of the skin, the platform gives clinicians a measurement that is more accurate and repeatable, cutting variability and making clinical workflow more efficient. By bringing greater objectivity and efficiency to lymphedema assessment, the platform helps build confidence in clinical decision-making and lets providers devote more time to patient care. Alongside real-time measurement, the platform also enables longitudinal surveillance and monitoring, so clinicians can follow changes as they occur, including disease progression and response to treatment. Past the clinical advantages, the patient experience is on another level. The 3D model measurement output provides a compelling visual of the patient's chest, trunk, head, neck, and/or limb, which helps them grasp their condition better and keeps them engaged in managing their disease across the care journey. We anticipate these digital measurement abilities will allow more accurate disease identification and thus speed therapy access for the 20 million undiagnosed symptomatic patients in the United States. This deal represents a milestone in Tactile's shift from a product-based company into a comprehensive integrated solutions leader for lymphatic dysfunction. With Tactile and LymphaTech joined, we are uniquely positioned to serve patients and clinicians from early identification and intervention through innovative connected therapy, with long-term support and monitoring alongside our Kylee patient engagement application. We expect this acquisition to directly bolster our longer-term strategy as we look to capitalize on the growing scientific and clinical understanding of lymphatic dysfunction and lead the next wave of technological innovation; we are very excited about this announcement and for the LymphaTech team, who share our combined passion for providing advanced solutions to large, underserved patient populations, to join Tactile. We will share additional details about the integration on subsequent calls. Now I'd like to walk through the latest developments across our 3 strategic priorities. These priorities were crafted to open up our TAM and make scalable, profitable growth possible, and they'll stay in our focus as we progress through 2026. Let me start with news on our foundational priority — enhancing access to care — and more specifically, our head and neck lymphedema RCT. To begin, I'm happy to report that in January, the Journal of the Sciences and Specialties of the Head and Neck published the 2-month findings from our RCT, which compares Flexitouch Plus against usual care for patients suffering from head and neck lymphedema. Those findings — first shared at the ASCO annual meeting this past June — led to the conclusion that, for head and neck cancer survivors dealing with lymphedema, Flexitouch Plus works as an effective first-line treatment when measured against therapist-guided treatment delivered without a compression device. Second, after we presented long-term RCT data at the ACRM fall conference in October, I'm glad to say the 6-month manuscript has now been submitted and is under review. We'll submit further manuscripts during this year, among them a deeper look at structural barriers tied to usual care and at how device technology can play a role in relieving the debilitating symptoms this population faces more quickly. This study is genuinely a landmark. There has never before been a large RCT evaluating both short and long-term outcomes of advanced pneumatic compression therapy as an evidence-supported substitute for usual care among treatment-naive head and neck cancer survivors with lymphedema. We're using these data to bolster our continuing conversations with commercial payers about the experimental and investigational policy language they currently apply to head and neck lymphedema device therapy. Clinical data and patient value examples such as these reinforce our oncology channel engagement and help raise awareness of the clinical benefits Flexitouch Plus offers patients in this therapeutic area. Although extensive coverage has yet to be fully opened up, the growing momentum and interest encourage us, and we'll keep working with commercial payers to shape their policies and lower access barriers. In addition to clinical evidence, we're concentrating on better access to care by reworking every step of the order process, achieved through deploying new technology and more efficient workflows. One essential piece of that effort involves AI-enabled technology that boosts speed, accuracy, and efficiency for PCD orders. In the fourth quarter, we finished the first phase of our new AI platform, rolling it out across our order intake process and for certain portions of our medical record review — particularly for orders within our Medicare channel. With the foundation in place and early learnings gathered from that initial rollout, we'll keep broadening this technology's use throughout the whole order process during this year, covering patient eligibility and verification of benefits, full medical record review and order qualification, and prior authorizations. After it’s fully in place, we anticipate that this technology will speed up the time it takes patients to get therapy, cut down on mistakes that hurt revenue, and make operations more efficient — and every one of those should help drive better operating margins going forward. Now I’d like to take a few moments to walk through our 2026 product roadmap and our wider strategic focus on broadening treatment options; that focus touches both of our business lines and comes down to spotting unmet needs that persist and meeting them with innovation built around the patient; we made good on that in 2025 when we introduced Nimbl for upper and lower extremity lymphedema, and we remain very happy with how patients and clinicians have taken to it. Almost a full year since launching into a crowded market, we’ve become the market leader in the basic compression pump category, and we anticipate continued growth in that category and reaching more patients with Nimbl. Innovation in our products will open up future growth opportunities, and looking toward this year and further out, there are two particular additional innovation areas I want to call out. First, on the airway clearance side. In early Q4, we filed a 510(k) with FDA for the next generation of our AffloVest product. The product is still under FDA review, but we plan to launch it commercially later this year so that it’s on the market for the 2026 through 2027 winter respiratory season; we’re extremely enthusiastic about this next generation device, which will bring further weight reduction, added digital connectivity, and better sizing adjustability for a more customized fit...
We believe these improvements will bolster what patients go through and help them stick with their treatment. The advanced pump category is where our second innovation focus lies. For Flexitouch, our plan involves rolling out features and upgrades in stages, which means shrinking the device, reducing its weight, making it easier to operate, and cutting down on exterior tubing; these changes will aid the patient experience, and we'll share more news as we move through our development cycles during this year. More upgrades are coming and could bring novel capabilities that alter how therapy gets administered; thanks to buying LymphaTech, we've gained an expanded set of skills along with a distinct product plan from the team they brought aboard. During the coming months, we'll search for ways to merge the roadmaps, acting carefully and thoughtfully so that fresh therapies and designs boost what patients get from treatment without hurting how well it works. Boosting the value a patient brings over their lifetime by helping those with lymphedema through the entire care journey — that's what our third strategic priority targets, covering engagement that's more streamlined and tailored before, throughout, and following the ordering and delivery steps. Come 2026, our intention is to keep zeroing in on care navigation pilots that are targeted, using what we already have to strengthen how patients stay involved amid the intricate and lengthy ordering steps while cutting down on patient linkage. These pilots aim to connect with patients proactively at crucial points along the care journey, assisting in setting expectations, cementing what needs to happen next, and aiding prompt movement through the order workflow. Proof of concept has come from our first pilots, demonstrating that clearer communication and direction earlier on is something patients appreciate. Even as we keep assessing tech investments for the longer haul, our immediate attention stays on honing these pilots, fine-tuning where we communicate, and growing what they achieve in a way that's careful and can scale. This method, we think, will lift yield, make the patient experience better, and eventually lessen how much sales reps need to be involved in ordering. As is evident, we keep performing strongly across a varied range of strategic priorities crafted to open up our TAM and generate steady growth in the near, mid, and longer term. Ahead in every one of these areas lie numerous catalysts, such as ongoing commercialization, acceleration, and advancement on our product and clinical roadmaps, which we anticipate will fuel our momentum going forward. Having said that, I'll turn it over to Elaine to walk through our Q4 financial results in greater depth and give an update on our guidance and outlook for 2026.
Thank you, Sheri. Except where I say otherwise, every figure I mention for the fourth quarter is presented on a GAAP basis and compared with the prior year. Fourth quarter total revenue rose $80 million, or 21%, reaching $103.6 million. Looking at our product lines, sales and rentals within lymphedema — a category that covers our Flexitouch, Entre, and Nimble systems — were up $12.4 million, or 16%, coming in at $89.5 million. Revenue from airway clearance products, which is where our AffloVest system sits, grew $5.6 million, or 66%, to $14.1 million. Moving further through the PNL: gross margin came to 78.2% of revenue, versus 75.2% during the fourth quarter of 2024. That gross margin improvement stemmed mainly from reduced manufacturing costs along with better collections as reflected in our revenue. Operating expenses for the first quarter climbed $10.4 million, or 20%, totaling $62.2 million. Within GAAP operating expenses, the shift comprised a $4.7 million rise in sales and marketing, a $0.5 million rise in research and development, and a $5.2 million rise in reimbursement, general and administrative, driven largely by strategic investments. Operating income was up $6.3 million, or 50%, at $18.8 million. Interest income fell $0.3 million, or 28%, to $0.7 million, a result of lower cash positions. Interest expense declined $0.5 million, or 98%, to $11,000. Income tax expense rose $5.5 million, or 169% versus a year earlier, to $8.8 million. Net income grew $0.9 million, or 9%, to $10.6 million, equating to $0.46 per diluted share, up from $9.7 million, or $0.40 per diluted share. Adjusted EBITDA rose to $22 million, compared with $16.2 million. On the balance sheet, at quarter end we held $83.4 million of cash and cash equivalents with no borrowings outstanding. That compares with $94.4 million of cash and $26.3 million in borrowings outstanding as of December 31, 2024. Now to walk through our 2026 outlook: for the full year 2026, total revenue is expected to land between $357 million and $365 million, which works out to roughly 8%-11% growth versus the prior year; embedded in this guidance is an assumption that both lymphedema and airway clearance grow within a comparable overall range, with airway clearance expanding somewhat faster. As is customary, our guidance range captures a number of considerations, among them anticipated strength in airway clearance plus continued commercial momentum in lymphedema stemming from our go-to-market strategy. The guidance likewise takes into account a recent Medicare regulatory development concerning pneumatic compression devices. To be specific, CMS said in January that a new prior authorization requirement would apply to basic and advanced pneumatic compression device codes billed through traditional Medicare fee-for-service. Under this change, beginning April 13, medical device suppliers must secure prior authorization before they furnish such devices and submit claims to Medicare. Stepping back briefly, Medicare policy within our category remains — and has long been — a dynamic, evolving landscape. For years now, the pneumatic compression device codes affected by this latest update have appeared on the DME master list, which means they could be picked for prior authorization at any point. From what we understand, CMS goes through an annual review and update, and as part of that, some DME categories get shifted onto the required prior authorization list from time to time so there's extra oversight. What we're seeing here is a reflection of that wider CMS process — it isn't something aimed at Tactile or at any particular pneumatic compression device. At the end of the day, this new requirement means more administrative steps get added to the ordering process for Medicare fee-for-service patients. While the industry works through adjusting to it, we anticipate a short-term, temporary effect across the lymphedema market as a whole, and we've built that into our guidance for 2026. The key point is that we don't see this change affecting our capacity to grow in line with the overall lymphedema market during that stretch. As the industry leader and a DME provider that has been in this market a long time, we think we're positioned better than anyone to work through this; we already have deep experience operating under other prior authorization environments in Medicare Advantage and commercial plans, and the money we put into our back-office infrastructure, documentation workflows, and payer engagement capabilities in 2025 sets us up well to handle this transition efficiently. After the industry has adjusted, we look for the lymphedema market to get back to its normal growth trajectory. When that happens, we believe our scale, our experience, and our operating discipline put us in position to perform at least in line with the broader market. Stepping back, we think this change can be a positive for patients, since it helps make sure therapies are clinically appropriate and backed by evidence, which supports more consistent and timely access to care with fewer coverage disruptions. As we always do, we'll keep working closely with clinicians, payers, and patients as the industry moves through this change, so that access to therapy stays seamless and patient outcomes are optimized. Now on to quarterly shaping — we expect Q1 growth to come in higher than the rest of the year, driven by how last year's recovery was timed, with growth moderating as 2026 progresses. Against that backdrop, for modeling purposes for the full year 2026, we expect GAAP gross margin of roughly 76%, GAAP operating expenses up 8%-10% year-over-year as we annualize our sales organization investments and continue advancing our tech-related investments through the year, net interest income of about $3 million, a tax rate of 28%, and a fully diluted weighted average share count of roughly 22 to 23 million shares. For 2026, we expect to generate Adjusted EBITDA of approximately $49 million-$51 million; that outlook captures the annualization of 2025 investments along with continued strategic initiatives in 2026, which we see as important for supporting long-term growth and operating leverage. When it comes to our adjusted EBITDA outlook, we've factored in a few non-cash items: roughly $9 million for stock compensation expense, about $3.6 million for intangible amortization, and approximately $3.2 million for depreciation. That said, I'll hand things back over to Sheri for a few closing thoughts. Sheri?
Thanks, Elaine. We delivered strong results for Q4 and the whole of 2025, and everyone here takes real pride in what we've achieved and in the momentum behind us; we're carrying out our strategic priorities effectively, and the money we've put into our people and into a range of workflow processes is coming through and producing the returns we anticipated. Because of the base we've established across the last year, we feel confident about sustaining steady results that track overall market growth. Several catalysts lie in front of us — ongoing commercial momentum along with advances on our product and clinical roadmaps among them — and we therefore think we're heading into 2026 from a strong position. As everyone has observed, the payer policy landscape for Lymphedema is shifting, and having the industry's leading position means we're ready to adapt and answer effectively to whatever changes come our way. Our business has our confidence, and we're eager to bring you updates as 2026 unfolds. I want to express appreciation to the whole Tactile team for what they collectively put in during 2025. None of our results would have come about without them; and with that, operator, let's take questions now.
Hello, Kyle Winborne here, filling in for Adam. Nice work on a solid quarter, and we appreciate you fielding our questions. I think I'd want to begin with the Lymphedema segment. It turned in another robust showing during Q4 and honestly gained real traction across the latter half of the prior year. Could we dig a bit deeper into what powered that? Did you begin to observe the NCD interpretation really shifting into a favorable force during Q4, the way you previously described? We're simply noticing genuinely solid output and results stemming from the added staff, as you mentioned during your prepared remarks. Would you mind breaking down that segment's results for us?
Yes. Hello, Kyle. You essentially listed everything I had planned to mention. Truly, what we observed during Q4 was a combination of several investments across personnel, processes, and technology converging, which genuinely allowed the company to exceed what was expected; so certainly, having the CRM available — we discussed this — which went live twelve months back, roughly around now. Once Q4 arrived, adoption had become quite strong. Information was flowing in. It had genuinely become part of how our sales team operates day to day. Another element of our market approach involved simply growing our rep count. And as you noticed, we experienced a pleasant speedup in both recruiting and bringing reps aboard. A large number of them joined during Q2 and Q3, so they began delivering greater output by Q4. Beyond that, I'd note we did experience a slight favorable push from Medicare beneficiaries transitioning straight to Flexitouch based on the updated NCD rules. That was a factor which, as you're aware, we kept holding back on, refraining from fully embracing it until we felt more assured the policy had stabilized and been clearly established. Still, we did begin seeing a portion of that materialize, which was encouraging, and that's momentum we anticipate continuing throughout 2026. Additionally, regarding our airway — you didn't bring it up, but I'll mention our airway clearance division anyway; it performed excellently. Once again, this stemmed purely from our strategy and from carrying out those partnerships plus the instruction and training we provided. So those elements combined to produce an outstanding year, an outstanding quarter, and on the whole a truly outstanding year.
Thanks; that's really useful. So, I want to build on that regarding the lymphedema segment when we think ahead to 2026, and try to get a handle on the guidance you provided, particularly that revenue growth figure for the whole company. When we consider those new prior authorization rules you mentioned, plus the favorable factors that are only now beginning to take effect from the NCD, could you help us weigh those against each other? Did one cancel the other out? How did you account for those negative and positive pressures regarding reimbursement as we head toward 2026? Thanks.
Certainly; this aligns closely with how we approach guidance. The forecast we shared reflects a carefully balanced and considered view using what we currently know; when I consider the positive momentum, we've got the NCD, and our sales team is far more experienced now. They're performing well. By the close of Q4, we have all the representatives required; that 1:1 ratio we mentioned is in place. That means alongside each account manager, there's a product specialist. The patient population remains unchanged; it's still an underserved group. Our channel strategy is quite robust. So everything is set, and we expect to keep moving ahead; certainly, the shift that Medicare's requirement introduces for prior auth differs from what we experienced in 2025. However, the reality is we'll be ready for it; we already handle prior authorization for our commercial operations; now we need to establish it for Medicare. This category has never been subject to prior authorization by Medicare before, so they'll be figuring it out too. Thus, we thought it wise not to move too quickly here. We're ready. We'll tackle it. And, as we figure out what's needed and how patient flow will look, we can always revise our guidance in Q3 once we gain more familiarity in this area; but indeed, we factored in both negative and positive elements, yet this prior auth represents a near-term obstacle that we're well equipped to handle.
Super helpful. Thank you.
Thanks.
Hello Elaine, hello Sheri — this is Izzy calling in place of Ryan. Appreciate you taking our questions. Sorry about whatever noise might be coming through in the background. I'd also like to add my congratulations on a strong quarter. To kick things off, I was hoping you might expand a bit on the LymphaTech acquisition announced earlier today. Is there any detail you can share regarding how you expect to commercialize it, or any big-picture thinking for us to factor into our 2026 models now that this deal is coming in?
Of course. Hello, Izzy. We couldn't be more enthusiastic about bringing this acquisition into our business. Once again, both myself in earlier leadership roles and all of you have kept asking how we might unlock that TAM — those 20 million patients across the U.S. by itself who live with lymphedema yet remain undiagnosed; so it aligns beautifully with our broader strategy and that continuum of care; we're extremely excited about it. Something else that has us genuinely thrilled is, first, that they already sell a commercialized product, meaning the commercialization model as it stands today involves use for measurement and surveillance, with compression garment makers relying on it for digitizing, fitting, and ordering. Beyond that, a handful of centers use it simply as one piece of their overall workflow. Further out, we see a chance to fold LymphaTech into our commercial engine, place it with our rep teams, and pursue a highly strategic segmentation approach for selling it into those centers with large volume, where workflow efficiency will truly matter. On top of that, you get a terrific patient experience — no one is wrapping a tape measure around your limbs with results varying depending on who performs it; here it's no touch, and the patient can actually view what their fluid volume looks like in their limbs. That's very sticky for helping them grasp the disease they have. So at present we aren't placing it in our reps' bags; it is certainly available on the market. There's also a regulatory and reimbursement strategy underway, and we'll examine how to keep building that out so that, you know, a payment mechanism exists for clinicians using the tool; but more of the specific work will happen once we get into integration. And once more, we're just incredibly excited to have this in the portfolio now, truly cementing and solidifying, you know, our strategy of leading in this space and offering that complete care continuum of technologies and solutions for patients and clinicians alike.
Understood, that's useful. Then, returning briefly to the guidance, I wanted to know what brings it to 8% rather than 11%, given every headwind and tailwind you mentioned for the year, plus the reimbursement situation. Thank you for answering.
Of course. I think that lower figure of eight. Several factors, particularly from a Lymphedema perspective, we stated a year ago, and will repeat, that our belief is we will expand in line with the market. Our view is this prior auth will probably reduce some of that market expansion. That 10% figure captures certain years being stronger and certain years being weaker, and reimbursement has played a major role in it being stronger or weaker. So my expectation would be an 8% if the prior auth proves, you know, truly difficult, not so much for us, but for the, the reviewers; it will be a manual process. It isn't an AI process. They need time to get up to speed. Should they be extremely cautious, fail to receive training. I mean, those kinds of factors could push it lower, which is what we viewed as dragging toward the bottom end. Yet nothing else is fundamentally unsettling the business as such. Once more, patients exist, our channels are present. We possess the largest sales force in our history. We're operationalizing our back office. We have CRM tools; thus all these elements are offsetting what could be a small portion of that short-term drag.
Hi there, I appreciate you fielding my question. I'd like to pick up where the previous one left off regarding the NCD modifications. Perhaps you could begin by offering us some additional detail. As you noted, you've already been handling prior authorization on the commercial side for some time now. Could you walk us through what that workflow actually involves? Given that you now possess substantial experience with both CMS and private payers, to what extent might a prior authorization requirement draw out the timeline for CMS beneficiaries in particular? I ask partly because I'm attempting to figure out what has already been baked into the 2026 guidance. Is the market going to shrink for one or two quarters and then start expanding again? Is that assumption part of what you've built into your guidance, or will this stay a growing market over the coming couple of quarters?
Yes, I'll hand things over to Elaine for some of the details. I just — earlier you mentioned a change to the NCD, and I want to be certain that the... There's no change happening with the NCD, so it remains as it is, and that, in our view, has really become a headwind, in the sense that patients meeting the criteria for an advanced pump are able to receive an advanced pump. What makes this situation distinct is that the fresh rule applies just to Medicare fee-for-service prior authorization, and it has no connection whatsoever to an NCD. That said, I'll hand things over to Elaine so she can describe how the prior auth procedure works within our commercial operations.
So yeah, essentially what happens is you put together a packet, which typically includes some form of cover letter containing the particular details a payer wants, along with all the documentation that backs it up — medical records. It might also be proof that the patient can put the device on and take it off, and all that gets sent in, whether by fax or through their portal, and then we'd typically locate a reply by looking at the portal. Now, that does drag things out. And that's what we've observed on the commercial side. Some payers we deal with respond very fast, while others take more time. As I believe you're aware, there's been a lot of public attention on this whole topic of obtaining prior authorization with a much quicker turnaround. I think the goal is really to get that done inside 7 days, so we're hoping we begin to see the same development with Medicare. So really, when we consider — to pick up on your point — whether this is a near-term sort of deceleration for the industry, that's what I think we're indicating: nothing fundamental is shifting. In the industry and with Medicare, we simply have to figure out this new process; and it truly comes down to a mix of the technical specifications regarding precisely what will make up all the components of that submission packet, and how we can most efficiently move information back and forth with Medicare, plus any of the bureaucracies when it comes to what they require; so we're quite seasoned, and we also have the capability, thanks to our new technology, to be far more agile when putting changes into place. So that's why we're recognizing it might, for a brief period, somewhat restrain the industry's growth, but we believe we're very well positioned to work through this. And so we don't view this as, you know, a major sort of longer-term headwind for us.
All right, excellent. Perhaps we move to another subject for a moment, Elaine — I believe, and please tell me if I've got this wrong, that this quarter likely represents the strongest EBITDA margin the company has ever posted. Could you spend a little time on where the greatest leverage is coming from, and then how far the EBITDA margin might climb from here? Obviously, you provided a 26 guide, but within the P&L, where do you see the largest chances for further leverage? Thanks, and once more, congratulations on a strong quarter.
Yes. Thank you for noticing that; it's something we've felt good about, the ability to expand profitability. Looking back at how we began the year, this is significantly better than what we had anticipated; so I'd say it reflects a mix of genuinely strong discipline around managing costs, plus beginning to realize returns on the investments we've been making. As we discussed, even certain AI tools are now delivering results. Going into this year, our guide points to an increase — a more moderate one — and that reflects a couple of things: annualizing certain investments, like our sales force. We didn't bear that expense across the entire year; we will, in the year ahead, in 2026, and we'll also be completing the strategic investments currently in progress. So we're pleased that margin expansion can continue, though somewhat more modestly this year, while those investments carry on. Over the longer term, after these investments are behind us, we do anticipate gross margin rates rising more quickly than what we're projecting for 2026.
Good afternoon, and thank you for taking the questions. To start with, speaking for myself, regarding the prior authorization, it doesn't sound like you have the specific requirements that CMS is going to be demanding, just for clarity's sake. And based on your past work with commercial insurers, it also doesn't sound like there's anything that is kind of out of the box, where clinicians are not used to kind of collecting the data, and it's more of a question of how quickly CMS can turn it around. Is that the right way to think about this here?
So what I'd say about Medicare is that it's been a process of daily learning for us. We do have a sense of which forms have to be completed, you know. We're fairly confident, since keep in mind that approvals come after the claim; so we're fairly — we have a solid grasp of the criteria Medicare applies when deciding whether a claim succeeds, and that ought to carry over quite smoothly into the prior auth setting. That said, certain technical questions remain, like what's the optimal submission method? Will there be elements that differ somewhat from prior auth? So that's essentially where the learning is happening. Sadly, no two payers operate the same way, so nothing exists that works straight off the shelf; even so, we're eager to be using some of our more recent technology that employs AI to assist in facilitating and establishing this process; so I believe, you know, that this is something we're eager about, since it will help not just in making things more efficient on our end, but ideally in shortening that turnaround time for patients too.
All right, that's useful. Then, regarding the bronchiectasis medication that came to market in this country several months back, are you noticing any effect when it comes to expanding that market? What sort of detail can you share on that?
Sure. What I mean is that in our airway clearance business, the patient group closely resembles the underserved and underdiagnosed people we encounter with lymphedema. So when it comes to growth in bronchiectasis—or at minimum, awareness of it—I'd attribute that to, let's say, pharma companies entering the space, which generated far more disease awareness, plus training and education delivered to the pulmonology and respiratory community. As a result, we've observed a solid increase on that front. Another positive aspect here, Ben, is that no guidelines exist, and no clinical decision exists, saying a drug ought to be used before this therapy. The intent is for them to be used in combination. Drug therapy brings inflammation down, yet it doesn't truly shift the mucus, and that's the major difficulty these patients face once mucus builds up and then infection follows. So the two are going to complement each other very well, and therefore we value the greater awareness around the disease state, and we also value that our physician ranks among our top ten DMEs, holds the preferred placement, and is seeing growth. So for us, this remains a highly attractive market, with many patients who still need care.
Understood — that covers everything on my end. Nice work on the quarter, and I appreciate you fielding the questions.
Yeah. Thank you, Ben.
That brings us to the end of the Q&A. Everyone, we appreciate you joining us; today's teleconference is now finished. Please go ahead and hang up, and enjoy the rest of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Tactile Systems Technology, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Tactile Systems Technology, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.